Skip to content
Screener

LivaNova LIVN Neuromodulation — Operating Income

Other segment segments

Cardiopulmonary
$28.15M-10.4%

Similar metrics at other companies

Lincoln Educational Services Corporation logo
LINCCampus Operations — Operating Income
$27.73M+28.0%
DWS
DWSNCanada Operations — Operating Income
$5.4M-2.8%
Southern Copper logo
SCCOPeruvian Operations — Operating Income
$923.7M+64.5%
Falcon's Beyond Global logo
FBYDDestination Operations — Operating Income
-$242K+36.3%
Erie Indemnity Company logo
ERIEManagement Operations — Operating Income
$166.79M+10.2%
Universal Corporation logo
UVVIngredients Operations — Operating Income
$1.82M-58.5%

Other financials

Income statement

See full
Revenue$390.6M+10.8%
Gross profit$273.7M+14.5%
Operating income$49.5M-8.7%
Net income$108.6M+300%
EPS (diluted)$1.93+286%

Balance sheet

See full
Cash & equivalents$516.6M-13.0%
Total debt$348.5M-27.8%
Total equity$1.3B+18.0%
Total assets$2.6B+5.4%

Cash flow

See full
Operating cash flow$66.6M+5.8%
CapEx$31.6M+108%
Free cash flow$35.0M-26.7%

Valuation

See full
Market cap$4.17B+61.5%
Enterprise value$4.01B+61.9%
P/E22.6×-67.9×
P/S2.8×+0.9×

Profitability

See full
Gross margin68.1%+0.1pp
Operating margin12.7%-0.7pp
Net margin-16.1%-18.0pp
FCF margin10.1%-2.3pp

Returns & leverage

See full
Return on equity-17.6%-19.5pp
Debt / equity0.3×-0.2×
Current ratio1.4×+0.2×

Where this comes from

Reported directly by LivaNova in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The source filing: LivaNova’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 2:23 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001639691-26-000090
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Cardiopulmonary$28,152$31,407$58,219$56,098
Neuromodulation60,93556,020105,089108,373
Segment income89,08787,427163,308164,471
Other expense(39,603)(33,244)(72,353)(61,671)
Operating income49,48454,18390,955102,800
SNIA environmental liability expense(1,677)(362,070)
Interest expense (1)(7,176)(14,931)(15,467)(30,217)
Foreign exchange and other income/(expense)(23,829)(4,255)(29,524)7,161

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is LivaNova's neuromodulation — operating income?
LivaNova (LIVN) reported neuromodulation — operating income of $60.94M in Q2 2026.
How has LivaNova's neuromodulation — operating income changed year-over-year?
LivaNova's neuromodulation — operating income increased by 8.8% year-over-year, from $56.02M to $60.94M.
What is the long-term trend for LivaNova's neuromodulation — operating income?
Over 3 years (2021 to 2025), LivaNova's neuromodulation — operating income has grown at a 8.3% compound annual growth rate (CAGR), from $169.5M to $215.47M.
What does neuromodulation — operating income mean?
Calculated as the segment's net revenue minus cost of sales and operating expenses, excluding interest and taxes. It measures the core profitability and operational efficiency of the Neuromodulation business unit.

Ask your AI about LivaNova's neuromodulation — operating income.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude